Objectives: To measure setup and intrafraction variability for intracranial targets during treatment of patients immobilized with a Brainlab, Inc. thermoplastic head mask using ExacTrac© imaging on the treatment unit.
Patients And Methods: Between November 2007 and June 2008, 12 patients were treated with cranial fractionated stereotactic radiation therapy for 25-28 fractions. Patient offset was calculated by the ExacTrac© algorithm from the planning computed tomography and orthogonal kV images taken at the time of treatment. Shifts of the patient position were done when the initial offset was greater than 1.5 mm. If a shift was made, post-shift images were acquired before treatment. Images were also acquired post-treatment to determine intrafraction movement.
Results: A total of 849 pairs of images were obtained. The averaged results of all 12 patients were: setup offset was 1.98 mm, treatment offset was 0.57 mm, and post-treatment offset was 0.66 mm. Of 303 fractions treated, 30 fractions had a post-treatment offset greater than 1.5 mm.
Conclusion: Quantitative analysis of the data set including variability in patient setup and intrafraction motion shows patient position can be reproduced within 1.0 mm using Brainlab thermoplastic head mask systems using the ExacTrac© system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jmir.2012.07.001 | DOI Listing |
Strahlenther Onkol
January 2025
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
Purpose: This study aimed to evaluate the prognostic significance of magnetic resonance imaging (MRI) parameters on biochemical failure-free survival (BFS) in patients diagnosed with intermediate-risk prostate cancer and treated with robotic ultrahypofractionated stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT).
Methods: A retrospective analysis was conducted in patients with intermediate-risk prostate cancer undergoing robotic SBRT delivered in five fractions with a total radiation dose of 35-36.25 Gy.
Neurosurgery
September 2024
Department of Surgery, Division of Neurosurgery, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Background And Objectives: Oligodendrogliomas are primary brain tumors classified as isocitrate deshydrogenase-mutant and 1p19q codeleted in the 2021 World Health Organization Classification of central nervous system tumors. Surgical resection, radiotherapy, and chemotherapy are well-established management options for these tumors. Few studies have evaluated the efficacy of stereotactic radiosurgery (SRS) for oligodendroglioma.
View Article and Find Full Text PDFGlobal Spine J
January 2025
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Study Design: Narrative review of existing literature.
Objectives: Significant technological advancements in radiotherapy planning and delivery have enabled new radiotherapy techniques for the management of spine tumors. The objective of this study was to provide a comprehensive summary of these treatment techniques for practicing spine surgeons.
J Clin Neurosci
January 2025
Lausanne University Hospital (CHUV), Neurosurgery Service and Gamma Knife Center, Switzerland; University of Lausanne (UNIL), Faculty of Biology and Medicine (FBM), Switzerland; Ecole Polytechnique Fédérale de Lausanne (EPFL, LTS-5), Switzerland. Electronic address:
Introduction: Stereotactic radiosurgery (SRS) is one of the treatment options for the management of residual or recurrent secreting pituitary adenomas (PA). While the role of radiosurgery (RS) by Gamma Knife (GK) has been clearly established, Cyberknife (CK) RS has been evaluated in fewer series.
Material And Methods: To perform a systematic review of the literature and meta-analysis, with the aim of focusing on the effect of CK RS on secreting PA.
Strahlenther Onkol
January 2025
Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Purpose: Our objective was to identify the dosimetric parameters and prostate volume that most accurately predict the incidence of acute and late gastrointestinal (GI) and genitourinary (GU) toxicity in prostate cancer stereotactic ablative radiotherapy (SABR) treatments.
Methods: We conducted a retrospective analysis of 122 patients who received SABR for prostate cancer at our clinic between March 2018 and September 2022 using a five-fraction SABR regimen. The existing plans of these patients were re-evaluated according to our institutional protocols (Hacettepe University [HU-1] and HU-2) as well as PACE‑B, RTOG 0938, and NRG GU005 dose-volume constraints.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!